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About This Report 
 
About NLCAHR 
The Newfoundland & Labrador Centre for Applied Health 
Research, established in 1999, contributes to the 
effectiveness of the health and community services system 
of the province and the physical, social, and psychological 
well-being of the population. NLCAHR accomplishes this 
mandate by building capacity in applied health research, 
supporting high quality research, and fostering more 
effective use of research evidence by decision makers and 
policy makers in the province’s health system.  
 
About the Contextualized Health 
Research Synthesis Program 
In 2007, NLCAHR launched the Contextualized Health 
Research Synthesis Program (CHRSP) to provide research 
evidence that would help guide decision makers in the 
provincial health system on issues of pressing interest to 
Newfoundland and Labrador. Instead of conducting 
original research, CHRSP analyzes findings from high level 
research already conducted in the subject area, such as 
systematic reviews, meta-analyses and health technology 
assessments. Findings are then synthesized and subjected 
to a systematic process of contextualization: they are 
analyzed in terms of their applicability to the conditions 
and capacities of the unique context of Newfoundland and 
Labrador. Our contextual analysis includes assessing the 
specific forms an issue may take in this province as well as 
the applicability of any proposed solutions and methods to 
locally available resources, infrastructure, human 
resources, cultural conditions and financial capacities. 
CHRSP uses a combination of external experts and local 
networks to carry out and contextualize the research 
synthesis and to facilitate the uptake of the results by 
research users. CHRSP focuses on three types of projects: 
health services/ health policy projects, health technology 
assessment (HTA) projects, and projects that combine the 
two to examine processes for the organization or delivery 
of care involving a health technology. 
 
About Our Partners 
For this project, NLCAHR partnered with Eastern Health. 
Senior administrators from Eastern Health proposed the 
original CHRSP topic and participated on the CHRSP Project 
Team through the contextualization of the synthesis 
results to the drafting of the final report. Other members 
of the CHRSP Project Team included senior decision 
makers and local experts from the four provincial Regional 
Health Authorities and Emergency Department 
practitioners who provided additional contextualization 
analysis and contributions to the writing of the report. 
Who Should Read This Report? 
This report provides a synthesis of the relevant research-
based evidence on the clinical effectiveness, feasibility and 
acceptability of cardiac troponin point-of-care testing for 
emergency departments in Newfoundland and Labrador in 
general, and for smaller hospitals and health centres in 
particular.  In addition to the synthesis of research-based 
evidence, this report also provides an analysis of local 
contextual factors and the impact they may have on lab 
services in the province. This report is intended to inform 
and assist decision makers in the Department of Health and 
Community Services of Newfoundland and Labrador and 
the province’s Regional Health Authorities who are involved 
in the planning, implementation and delivery of services. 
This CHRSP report is also meant to help guide decisions 
regarding lab services and the provision of point-of-care 
testing in emergency departments in the province. 
This report is also aimed at practitioners, researchers and 
other stakeholders involved in providing emergency health 
services in settings that do not have 24/7 central laboratory 
services. Decision makers from other jurisdictions, especially 
those with similar geography, resources and potential client 
populations, may also find the content helpful. The report 
includes explanations of research terms and technical 
language; accordingly, there is no need to have a specialized 
medical or health background in order to understand its 
content.   
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Glossary 
 
Acute Coronary 
Syndrome (ACS) 
A term used to describe any condition that results in a sudden reduction 
in blood flow to the heart.  ACS is the result of coronary arteries 
becoming narrowed or blocked. The three types of ACS are ST Elevated 
Myocardial Infarction (STEMI) or Non-ST Elevated Myocardial Infarction 
(NSTEMI) and Unstable Angina (UA).  
AMSTAR An 11-item instrument used to assess the methodological rigor of 
systematic reviews (1)  
Blinding Experimental design feature in which the research participants and/or 
researchers do not know if the participant is in the test group or control 
group. In ‘single blind’ experiments, participants are not aware of their 
group status. In ‘double blind’ experiments, researchers are also not 
aware of the participants’ group status.  
Blood gas test A type of test that measures the partial pressures of oxygen and carbon 
dioxide in the blood as well as the acidity (pH) of the blood. Results from 
this type of test can provide an indication of certain medical conditions 
or critical states.  
Callback lab services A service arrangement where medical laboratory staff can be ‘called 
back’ after hours to work. Newfoundland and Labrador medical 
laboratory staff are required to be paid for a minimum of three hours for 
a callback. 
Cardiac troponin Troponin is a type of protein complex made up of three individual 
proteins (troponin C, I and T). They interact to control striated muscle 
contraction, i.e., cardiac and skeletal muscle. Cardiac troponin I (cTnI) 
and T (cTnT) take a unique form in cardiac muscle. They are released into 
the blood when heart muscle cells have been damaged (2).  
Cardiac troponin 
testing 
Testing that measures the level of cTnI and cTnT in the blood stream in 
order to determine the severity of damage to the heart, in particular in 
cases of acute myocardial infarction (3). 
Coefficient of Variation 
(CV) 
Relative error expressed as a percentage and is the ratio of the standard 
deviation to the mean times 100. It indicates the extent of variability in 
relation to mean of the population. 
Complete Blood Count 
(CBC) 
A test that is ordered when a person exhibits signs and symptoms that 
may be related to disorders that affect the blood. CBC measures the 
concentrations of the cellular elements of the blood, including white 
blood cells, red blood cells, platelets as well as hemoglobin and 
hematocrit (% of a person’s blood that consists of red blood cells). 
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Confidence Interval 
(CI) 
A measure of the reliability of an estimate. A CI specifies a range within 
which the true value of an estimated parameter is expected to lie. CIs for 
ratios that include the value of 1 and CIs for differences that include the 
value of 0 indicate that the test and control groups are not likely to be 
different.  
Cost-effectiveness 
study 
A study in which the monetary costs of an intervention are considered in 
terms of a single common health outcome that is measured in natural 
units, for example: the number of years with full mobility gained from a 
treatment or the number of placements in long-term care that are 
deferred. 
Cost-minimization 
study 
A study that analyzes alternative interventions that are assumed to 
produce equivalent outcomes in order to determine which of those 
interventions is least costly (4).  
Cost-utility study A study in which the monetary costs of an intervention are considered in 
terms of a single outcome, or considered in terms of multiple outcomes 
that are weighted or valued in relative terms. The combined outcome is 
measured in units that capture both the quantity and quality of the 
effects of the intervention, with the most common measure being the 
quality-adjusted life-year or QALY. 
Clinical biochemistry 
test 
A class of clinical pathology tests that relies on measuring various 
chemical constituents in serum and plasma, whole blood, urine and 
other body fluids. Clinical biochemistry tests may be used to confirm a 
diagnosis, screen for a disease, assist in the evaluation disease risk or 
prognosis. 
Cytological tests A class of clinical pathology tests that relies on testing at the cellular 
level in order to detect cell abnormalities. 
Diagnostic odds ratio A statistical measure of the effectiveness of a diagnostic test that 
expresses the strength of association between a test result and a 
disease. A large odds ratio generally indicates a high probability that the 
patient has the disease; conversely a low ratio is consistent with a low 
probability of disease.  (See odds ratio).  
Downs and Black 
Assessment Tool 
A checklist that was developed to assess the methodological quality of 
both randomised controlled trials and non-randomised studies (5). 
Effect size A measure of the strength of a relationship between two variables, for 
example between a treatment for a health condition and recovery from 
that health condition. Effect sizes may be quantified by a range of 
different measures, including correlations, differences in means and 
relative risks. 
Effectiveness The ability of an intervention to produce the desired beneficial effect in 
actual usage. 
Efficacy The ability of an intervention to produce the desired beneficial effect in 
expert hands and under ideal circumstances. 
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Electrolyte testing Measurement of the levels of different electrolytes in whole blood, 
serum plasma etc. (e.g. sodium, potassium, chloride and bicarbonate).  
Grey literature Research that is published non-commercially, which includes reports 
carried out by governments, health authorities and not-for-profit 
associations. 
Health technology 
assessment 
Research that that studies the medical, social, ethical and economic 
implications of the development, diffusion, and use of health 
technology. 
Incremental Cost-
Effectiveness Ratio 
(ICER) 
The ratio of the difference in costs between an intervention group and a 
control group to the difference in outcomes or effects between the two 
groups. Costs are most often measured in monetary units, while 
outcomes or effects are most often measured in terms of QALYs. 
Inter-Quartile Range 
(IQR) 
A measure of the statistical dispersion of a variable for a sample. The IQR 
is reported by the first and third quartile values for the variable in 
question, indicating the middle 50% of the sample. 
Inter-Rater Reliability 
(IRR) 
A statistical measure that quantifies the level of agreement between two 
or more raters. 
International 
Normalised Ratio (INR) 
A lab measurement that is used to determine how long it takes for blood 
to clot. 
Length of Stay (LOS) The time taken from patient registration or triage to the time the main 
service provider makes the decision to discharge the patient or to the 
time the patient is admitted (6).  
Liver function tests Blood tests used to assess the general state of the liver and biliary 
systems. These include tests for liver enzymes (e.g., alanine 
aminotransferase (ALT) and alkaline phosphatase), bile (e.g., bilirubin) 
and proteins (e.g., albumin), as well as tests that measure blood clotting 
(e.g., prothrombin time and INR). 
Markov chain A type of model that is based on random probability distribution that 
describes a sequence of possible events in which the probability of each 
event depends only on the present state and not on any past states. 
Meta-analysis A type of systematic review that uses statistical techniques to 
quantitatively combine the findings from primary research studies. 
Micro-costing study Micro-costing studies collect detailed data on resources utilized and the 
value of those resources. Such studies are useful for estimating the cost 
of new technologies or new community-based interventions, for 
producing estimates in studies that include non-market goods, and for 
studying within-procedure cost variation (7). 
Micro-simulation study A category of computer modeling that analyzes the interactions of 
individual units, e.g., patients or health professionals, in order to model 
the effectiveness of an intervention. 
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Myocardial Infarction 
(MI) 
The clinical name for a heart attack. The syndrome that results from 
blood not flowing properly to the heart.  
Negative likelihood 
ratio (NLR) 
One of two types of likelihood ratios that help determine which 
diagnostic test will best help to rule-in or rule-out a disease in a patient. 
A NLR indicates how much trust to place in a negative reading indicating 
that a patient does not have the disease in question. n. The more the 
NLR exceeds 1, the greater the likelihood that the patient does not, in 
fact, have the disease. See Figure 3, p. 14 for summary of test 
performance measures. 
Non-ST Elevation 
Myocardial Infarction 
(NSTEMI) 
A type of ACS that is moderately severe, caused by the partial blockage 
of coronary arteries by a blockage or clot. The ECG shows no ST segment 
elevation as there is with a ST Elevation Myocardial Infarction. 
Observer effect Occurs when a subject under study modifies their behaviour as a result 
of being actively observed. 
Odds ratio The ratio of the likelihood of an outcome occurring in one group 
compared to the likelihood of it happening in another group. An odds 
ratio of 1 indicates that there is no difference between the likelihood of 
the outcome happening in one group and the likeliness of its happening 
in the other. 
Positive likelihood 
ratio (PLR) 
One of two types of likelihood ratios that help determine which 
diagnostic test will best help rule-in or rule-out a disease in a patient. A 
PLR indicates how much to increase the probability that a patient 
actually has a disease if the test is positive. The more the PLR is over 1, 
the greater the likelihood that the patient does, in fact, have the disease. 
See Figure 3, p. 14 for summary of test performance measures. 
QALY A measure that combines time and an assessment of quality of life. QALY 
stands for “quality adjusted life year.” A QALY unit is based on a scale 
that considers one year of life lived in perfect health worth 1 QALY. A 
year of life that is lived in a state of less than perfect health is worth less 
than 1 QALY. The quality of life is quantified as “the utility value,” a 
measure of the state of health of the person in question. A QALY value 
equals the utility value multiplied by the years lived in that state: UTILITY 
x TIME = QALY. QALYs are expressed in terms of “years lived in perfect 
health.” For example, half a year lived in perfect health is equivalent to 
0.5 QALYs, the same as 1 year of life lived in a compromised state of 
health with utility 0.5 (6).  
Randomized 
Controlled Trial (RCT) 
A study in which a number of similar people are randomly assigned to 
two (or more) groups to test a specific drug/ treatment.  The 
experimental group receives the treatment being studied; The 
comparison or control group receives an alternative treatment, a dummy 
treatment (placebo) or no treatment at all. The groups are followed up 
to see how effective the experimental treatment was. Outcomes are 
measured at specific times and any difference in response between the 
groups is assessed statistically. This method is used to reduce bias (8).  
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Receiver Operating 
Characteristic (ROC) 
curve 
Used to measure the accuracy of a test, i.e., the test’s ability to 
distinguish those with and without the condition under examination. The 
ROC curve plots the test’s sensitivity against 1-specificity. If the area 
under the curve equals 1, the test perfectly predicts those with and 
without the condition. If the area under the curve equals 0.5, the test is 
random; its predictive value is equal to a coin toss and thus it cannot be 
trusted to predict those with and without the condition. 
Renal function testing A class of tests used to assess the state of renal functioning. Typical renal 
tests include measuring different blood components including 
creatinine, blood urea nitrogen, BUN (creatinine ratio), albumin, calcium, 
CO2, chloride, glucose, phosphorus, potassium and sodium. 
Relative Risk (RR) A measure of the likelihood that an exposure will have a particular 
outcome. In the case of health services, RR is the ratio of the probability 
of an outcome occurring in a test group that received the health service 
compared to the probability of its occurring in a control group that did 
not receive it. 
Sensitivity In the context of screening or diagnostic testing, the proportion of 
persons with the disease/condition who are correctly identified as 
positive by a test. A test with a high sensitivity produces very few false 
negatives. This is particularly useful for screening tests to rule out a 
diagnosis for a condition, since negative test results are very likely to be 
true negatives. See Figure 3, p. 14 for summary of test performance 
measures. 
Specificity In the context of screening or diagnostic testing, the proportion of 
persons without the disease/condition who are correctly identified as 
negative by a test. A test with a high specificity produces very few false 
positives. This is particularly useful for diagnostic tests to rule in a 
diagnosis for a condition, since positive test results are very likely to be 
true positives.  
ST-Elevation 
Myocardial Infarction 
(STEMI) 
A severe type of heart attack in which blood to the heart is completely 
blocked. Characteristic changes in ST elevation show major damage to 
the heart muscle as measured by an electrocardiogram. 
Systematic review A literature review, focused on a specific and explicit research question 
that applies a systematic methodology to identify published and 
unpublished research evidence relevant to that question, and then 
select, appraise and synthesize the evidence. 
Time to disposition Time from patient registration or triage to the time the main service 
provider makes a decision about the patient’s care needs, typically the 
decision to discharge or admit the patient (6). 
Trapezoidal rule In numerical analysis, the trapezoidal rule is a technique for 
approximating the definite integral. The trapezoidal rule works by 
approximating the region under the graph of the function as a trapezoid 
and calculating its area.  
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Turnaround time (TAT) Generally speaking, this is the name for the interval between the time a 
test is administered to the time the test result is available. Studies may 
define this term slightly differently depending on the hospital protocols 
in place.  
Usual care Another term for 'standard care'. 
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The Research Question 
 
“What do the scientific literature and local knowledge tell 
us about the clinical effectiveness, feasibility and 
acceptability of cardiac troponin point-of-care testing for 
emergency departments in smaller hospitals and health 
centres in Newfoundland and Labrador?" 
 
Key Messages 
 
The following key messages emerged from a synthesis of the evidence related to cardiac troponin point-
of-care tests (POCT).  Decision makers are also encouraged to review the Considerations for Decision 
Makers outlined at the end of this report, as these combine the evidence with local contextual factors 
that may have an impact in Newfoundland and Labrador (See Page 47). 
 
1. In terms of test performance, the sensitivity and specificity of currently available cardiac troponin 
point-of-care tests are sufficient for their use as screening tests.  Cardiac troponin POCT continues to 
improve at a significant rate and is becoming as accurate as central lab testing. (Effective 
Intervention) 
2. In terms of clinical outcomes, cardiac troponin POCT does not appear to increase the risk of adverse 
cardiac-related events or readmission rates compared to central lab testing for patients seen in 
emergency departments. (Promising Intervention) 
3. When compared to central lab testing, emergency department cardiac troponin point-of-care tests 
significantly and consistently reduce turnaround time for test results. (Effective Intervention) 
4. Cardiac troponin POCT appears to have the capacity to reduce emergency department process time 
outcomes compared to central lab testing, but it cannot achieve those outcomes by itself.  Other 
site-specific variables appear to have an equal or greater impact on those outcomes. Point-of-care 
testing must be considered in the full context of emergency department operations for 
improvements in patient throughput to be truly quantified. 
5. Point-of-care testing has the greatest impact on emergency department process outcomes in 
facilities without a 24/7 central lab service. 
6. The evidence for the overall cost benefits of emergency department cardiac troponin POCT is 
incomplete and inconsistent.  The findings on the overall cost benefits are not conclusive. 
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Background 
 
This point-of-care test (POCT) project was initiated through a topic submission from Eastern Health to 
the Contextualized Health Research Synthesis Program (CHRSP) asking us to address the use of POCT in 
smaller hospital and health clinic emergency departments (EDs) without 24/7 central lab facilities (i.e., 
Category B emergency departments, see below).  These emergency departments are located in rural or 
remote parts of Newfoundland and Labrador, although some are within an hour’s driving distance of a 
major hospital.  
Achieving adequate levels of medical testing in the emergency departments of 
smaller health centres requires the involvement of both medical laboratory 
services and departments of emergency medicine. From the perspective of lab 
services, providing high-quality and affordable testing in smaller health centres 
is a major challenge. Considerations include shortages in health human 
resources, challenges in maintaining quality testing, and being able to afford 
instruments and reagents at health centres with lower test volumes. From the 
emergency medicine perspective, the main issue is having a test available to 
expedite patient care decisions by the attending physician.  As one of our 
project consultants told us:  
 
The greatest value that can be provided by [point of care] testing is through the 
provision of timely test results in emergent cases for immediate patient 
management decisions. The timely availability of a small critical care testing 
menu can potentially offer the most significant impact on patient outcomes in 
rural health care centers. 
As a result, the Regional Health Authorities (RHAs) and the Department of Health and Community 
Services (DHCS) are interested in point-of-care testing as a potential alternative to 24/7 lab services for 
emergency departments in smaller hospitals and health centres. Furthermore, the provincial health 
system plans on becoming accredited for POCT in emergency departments by 2015, and so the issue of 
which tests to have available has become particularly relevant. 
The initial scope of the project included a broad range of clinical biochemical and hematologic tests that 
are commonly requested in emergency departments and are potential candidates for POCT.  These 
include tests for: troponin, electrolytes, complete blood count (CBC), renal function, blood gas, liver 
function and blood clotting.  In an effort to narrow the focus of this study to within manageable limits, 
the POCT CHRSP Project Team considered the following criteria:  
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1. The time course of the presenting conditions that would indicate the use of the POCT; 
2. The effects of the POCT result on treatment decisions; 
3. The potential impact on economic and process outcomes if the POCT were available; 
4. The availability of research-based evidence about that POCT. 
Weighing the merits of various tests for their potential impact in terms of the above criteria, the Project 
Team ultimately selected cardiac troponin point-of-care testing for suspected acute coronary syndrome 
(ACS)1 as the focus of this study.  The goal of this project was to investigate the research-based evidence 
concerning the effectiveness, feasibility and acceptability of cardiac troponin POCT in emergency 
departments in smaller hospitals and health centres.  The topic was therefore refined and articulated as 
the following research question: 
  
"What do the scientific literature and local knowledge tell us about the 
clinical effectiveness, feasibility and acceptability of cardiac troponin 
point-of-care testing for emergency departments in smaller hospitals 
and health centres in Newfoundland and Labrador?" 
 
The POCT CHRSP Project Team then identified a set of priority outcomes for the final report: 
 health service variables, including turnaround time and the overall time spent in the emergency 
department;  
 costs of implementation and operation; 
 the feasibility of accrediting staff to implement a troponin POCT standard;  
 quality control and forward compatibility, e.g., the capacity for a POCT system to accept inputs 
from later versions of the equipment.  
The Project Team had also hoped to develop a model for cardiac troponin POCT usage and costs/ 
benefits based on emergency department and central lab administrative data sets. Such a model could 
be used to contextualize the evidence and to inform the report’s list of considerations for decision 
makers.  Ultimately, however, the Project Team had to abandon developing the model as the result of 
difficulties and delays with the data request.2  
  
                                                          
1
 See Online Companion Document, CHRSP Topic Refinement, for more details. 
2
 See Online Companion Document, Data Request, for more details. 
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Emergency Department Lab Services in NL 
 
Newfoundland and Labrador has three types of emergency medicine settings, termed Category A, 
Category B, and Community Clinics in Labrador (see Figures 1 and 2 below). These are characterized as 
follows: 
 Category A: emergency departments in larger hospitals with a minimum of one physician 
dedicated to providing emergency services and onsite 24-hours a day. They are located in 
hospitals that have acute care beds and other specialty services. All Category A emergency 
departments have access to 24/7 medical lab services (9).  Based on 2011 census data, Category 
A emergency departments are within a thirty-minute drive for approximately 70% of the 
respective populations on the island of Newfoundland (331,270/485,358) and in the Labrador 
territory (20,570/29,178);  
 
 Category B: emergency departments in smaller hospitals and health clinics with a physician that 
is always available but may not be onsite. They are located in facilities that may or may not have 
acute care beds and other specialty services, are primarily in the more rural areas of the 
province, and have lower patient volumes. All Category B emergency departments have medical 
lab services during working hours (Monday to Friday, 8:00am-4:00pm). Most have callback 
medical lab services after hours but a minority do not (9). Based on 2011 census data, Category 
B emergency departments on the island of Newfoundland are within a thirty-minute drive for 
22% of the island’s population (103,697); 
 
 Community Clinics in Labrador: fourteen clinics in Labrador, mostly located in remote coastal 
communities, focus on primary healthcare and are staffed by small numbers of nurses and 
support staff. In cases of medical emergency, Community Clinic nurses consult with emergency 
medicine physicians located in one of the three hospitals in Labrador Grenfell Health with 
Category A emergency departments.  Airlift services can transfer emergency patients to the 
closest tertiary care centre if needed. Based on 2011 census data: Community Clinics in Labrador 
serve approximately one-fifth of the population (5,895).  
Table 1 on page 20 of this report provides a detailed breakdown of driving time catchment 
population sizes. It is important to note that the population catchments for the different types of 
emergency department are not mutually exclusive—a household may be within a thirty-minute 
drive of both a Category A and a Category B facility. 
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Figure 1: Emergency Departments in Newfoundland 
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Figure 2: Emergency Departments and Emergency Care Facilities in Labrador 
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Table 1: Types of emergency care facilities and their population size based on select catchment areas 
 
CATEGORY A EMERGENCY DEPARTMENTS Population (2011) 
Regional Health 
Authority 
Community (Facility Name) 30 Minute 
60 
Minute 
Total 
Eastern Health 
St. John's (HSC / Janeway / St. Clare's) 197,081 7,519 204,600 
Carbonear (Carbonear General Hospital) 30,609 11,596 42,205 
Clarenville (Dr. G.B. Cross Memorial Hospital) 11,183 7,793 18,976 
Burin (Burin Peninsula Health Care Centre) 12,157 6,908 19,065 
Central Health  
Grand Falls-Windsor (Central Newfoundland RHA) 23,312 1,832 25,144 
Gander (James Paton Memorial Hospital) 12,638 15,694 28,332 
Western Health Corner Brook (Western Memorial Regional Hospital) 30,550 8,715 39,265 
Stephenville (Sir Thomas Roddick Hospital) 13,740 3,427 17,167 
Labrador- 
Grenfell Health 
Happy Valley-Goose Bay (Labrador Health Centre) 7,552 1,921 9,473 
Labrador City (Captain William Jackman Memorial Hospital) 9,228 0 9,228 
St. Anthony (The Charles S. Curtis Memorial Hospital) 3,790 1,079 4,869 
CATEGORY B EMERGENCY DEPARTMENTS Population (2011) 
Eastern Health 
Wabana (Dr. Walter Templeman Health Centre) 10,046 162,290 172,336 
Whitbourne (Dr. William H. Newhook Community Health Centre) 10,107 63,089 73,196 
Placentia (Placentia Health Centre) 4,172 728 4,900 
Bonavista (Bonavista Community Health Centre) 6,198 2,101 8,299 
Old Perlican (Dr. A.A. Wilkinson Memorial Health Centre) 3,783 2,665 6,448 
Grand Bank (Grand Bank Community Health Centre) 4,322 6,978 11,300 
St. Lawrence (US Memorial Health Centre) 2,982 3,195 6,177 
Central Health 
New-Wes-Valley (Brookfield/Bonnews Health Care Centre) 3,107 4,378 7,485 
Botwood (Dr. Hugh Twomey Health Centre) 22,220 1,332 23,552 
Fogo Island (Fogo Island Health Centre) 2,380 257 2,637 
Lewisporte (North Haven Manor) 7,834 13,128 20,962 
Twillingate (Notre Dame Bay Memorial Health Centre) 5,105 2,391 7,496 
Springdale (Green Bay Health Centre) 4,629 2,969 7,598 
Baie Verte (Baie Verte Peninsula Health Centre) 2,620 3,029 5,649 
Buchans (A.M. Guy Memorial Health Centre) 775 99 874 
Harbour Breton (Connaigre Peninsula Health Centre) 1,711 1,250 2,961 
Western Health 
Norris Point (Bonne Bay Health Centre) 1,803 7,812 9,615 
Burgeo (Calder Health Centre) 1,464 0 1,464 
Channel-Port aux Basques (Dr. Charles L. LeGrow Health Centre) 6,288 2,092 8,380 
Port Saunders (Rufus Guinchard Health Centre) 2,151 2,073 4,224 
Community Clinics in Labrador Population (2011) 
Labrador-Grenfell 
Health 
Nain  1,190 0 1,190 
Hopedale 555 0 555 
Natuashish 930 0 930 
Makkovik 360 0 360 
Postville 205 0 205 
Rigolet 305 0 305 
Black Tickle 170 0 170 
Cartwright 515 0 515 
St. Lewis 205 0 205 
Port Hope Simpson 440 0 440 
Mary’s Harbour 385 0 385 
Charlottetown 480* 0 480* 
Sheshatshui 1,276** 0 1,276** 
Churchill Falls 635 0 635 
* 2006 Census Data; **2009 Indian Register Population for Atlantic First Nations 
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Health system administrators in Newfoundland and Labrador prioritize equitable access to health 
services but cannot afford the costs of maintaining around-the-clock labs for all emergency departments 
in the province.  Attending physicians in Category B emergency departments are faced with a 
problematic situation when they see patients at night or on the weekends who present with conditions 
that require lab testing.  If lab staff cannot be called back and a potential medical emergency is 
suspected, physicians must make patient management decisions with incomplete information. 
Physicians may wait until lab staff is available: they can admit patients overnight or send them back 
home. They may refer patients to the nearest hospital with an operating lab; however, referrals are 
often not convenient for patients living in rural areas, since it can mean driving more than an hour away 
and a significant number of these patients are older.  
About Point-of-Care Tests   
 
A point-of-care test (POCT), also known as a bedside test, is a type of portable technology that allows a 
medical test to be administered, analyzed, and read where the patient is located and without having to 
send a sample to a lab.  These tests can be used in hospital departments, health clinics or ambulatory 
care settings.  Administering POCT in Canada requires appropriate accreditation (10). The major appeal 
of point-of-care tests is that they can be administered and read by people who 
are not lab technicians to provide quick test results at the patient’s bedside.  
POCTs typically analyze a specimen (e.g., blood or urine) for a specific 
component like a protein, metabolite or other small molecule (11). These 
components are referred to as biomarkers or analytes.  POCT have been 
developed to detect a broad range of analytes. The POCT device may measure a 
single analyte, e.g., blood glucose meters, or it may be designed to measure 
multiple analytes from a single specimen using a single ‘test panel,’ e.g., a liver 
function panel that can measure seven or more biochemical constituents.  
The interpretation of POCT results depends on the device. Qualitative POCT 
involve reading a test strip for a binary or ordinal outcome, e.g., 
positive/negative or strong/moderate/weak.  Quantitative POCT produce a unit-
based measurement that can be compared to other test results (12–14). Typically, the point-of-care test 
evolves to become quantitative as it develops higher sensitivity to detect low levels of the target 
analyte. POCT design is also advancing to the measurement of multiple analytes in one test panel, 
including cardiac, cancer and infectious disease panels (11).  
All provinces in Canada now require accreditation of both central lab and point-of-care testing. 
Newfoundland and Labrador adopted an accreditation framework for medical testing based on the 
Ontario accreditation system in 2010. Prior to 2010, the province did not have an accreditation 
framework for biomedical testing.  Many hospital emergency departments may have implemented a 
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range of POCTs, the most common being glucometers and urinalysis dipsticks. At present, all central labs 
in the province are accredited for a broad range of medical tests, while accreditation for POCT has been 
deferred until 2015. This means that, at time of writing, no POCTs except glucometers have been 
implemented in emergency departments in the province. 
Regulatory agencies and professional bodies (e.g., the Medicines and Healthcare Products Regulatory 
Agency in the UK and the National Academy of Clinical Biochemistry in the US) have published guidelines 
and best practices to assist in the implementation of POCT.  They identify the following potential 
advantages for POCT (13, 14): 
 Turnaround time for test results is reduced; 
 The need for clinical invasiveness is reduced due to smaller sample volumes; 
 Access is increased to testing procedures in remote areas; 
 Access to lab testing outside regular lab hours is increased, and that improves service 
accessibility to at-risk groups; 
 Costs are reduced by triaging patients at points of clinical contact, reducing the length of stay, 
reducing the number of clinic visits and the number of admissions; 
 Monitoring is facilitated for those conditions that need frequent testing.  
At the same time, research on POCT in general has shown that there are also risks, since POCT can be 
unreliable, ineffective and/or cost ineffective if the following conditions are present (15):  
 The clinical site has a history of poor compliance with quality control and quality assurance; 
 The clinical site does not have the capability to perform the POCT and/or the ability to comply 
with regulatory guidelines; 
 A central lab can provide adequate turnaround time compared to POCT; 
 The POCT device has poor analytic or test performance; 
 The POCT device is prone to instrument malfunction or operator error; 
 The POCT is too expensive as compared to alternatives; 
 The POCT is not medically necessary or will not improve operational efficiency of clinical 
services; 
 The POCT is used for off-label applications, e.g., using glucose meters for the diagnosis of 
diabetes mellitus.  
ACS and Troponin POCT   
Acute coronary syndrome (ACS) refers to the clinical symptoms consistent with acute myocardial 
ischemia, the situation in which the heart muscle does not receive enough oxygenated blood.  ACS 
includes three clinical conditions:  unstable angina (UA), non-ST-segment elevation myocardial infarction 
(NSTEMI) and ST-segment elevation myocardial infarction (STEMI). Unstable angina and NSTEMI are 
closely related conditions: their pathophysiologic origins and clinical presentations are similar, but they 
differ in severity. A diagnosis of NSTEMI can be made when the ischemia is sufficiently severe to cause 
myocardial damage resulting in the release of cardiac troponin. In contrast, the patient is considered to 
have experienced UA if troponin cannot be detected in the bloodstream hours after the initial onset of 
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ischemic chest pain. White blood clots are found exclusively in patients with UA/NSTEMI, while STEMI 
patients have both red and white blood clots.   
The differences in the underlying pathophysiology of UA/NSTEMI and STEMI call for different 
approaches and therapeutic goals. In UA/NSTEMI, the goal of antithrombotic therapy is to prevent 
further thrombosis and to allow endogenous fibrinolysis to dissolve the thrombus and reduce the 
degree of coronary stenosis; revascularization is frequently used to increase blood flow and prevent re-
occlusion or recurrent ischemia.  In contrast, in STEMI, the infarct-related artery is usually totally 
occluded, and immediate pharmacological or catheter-based reperfusion is the initial approach, with the 
goal of obtaining normal coronary blood flow. 
Patients presenting with chest pain who are suspected of ACS represent the largest group of individuals 
who are admitted to hospital from emergency departments in the UK (17).  An estimated 300,000 to 
500,000 Canadians present to emergency departments with chest pain annually 
(19). Of these patients, an estimated 15%-25% receive a diagnosis of ACS while 
2%-5% are misdiagnosed as having a less urgent condition and discharged 
(19,20). Patients presenting with ACS require rapid and accurate evaluation in 
the emergency room (21). For patients suspected of having ACS, faster 
assessment and correct classification of risk means a greater chance of limiting 
heart damage and maintaining cardiac function.  
Identifying ACS can be complex and time sensitive (22). Physicians face several 
significant challenges in assessing a patient with chest pain and suspected ACS. 
First, they must correctly identify those at high risk for a heart attack as distinct 
from those at low risk; and, second, they must ensure that patients at high risk 
are held at the hospital and treated appropriately while low risk patients are 
discharged. According to the National Academy of Clinical Biochemistry Lab 
Medicine Practice Guideline (LMPG) for POCT, 2-5% of patients with acute myocardial ischemia are 
inappropriately discharged from the ED (14).  Reportedly, this type of inappropriate discharge is the 
leading cause of malpractice lawsuits against ED physicians in the United States (14). 
Assessing risk for ACS is based on patient history, clinical features, electrocardiogram (ECG) features and 
results from lab tests (16–18,23,24). Risk scores are used to predict the prognosis of the syndrome and 
to assist in determining the clinical course of action that will be taken. Most risk-stratification systems 
categorize patients into low, intermediate and high risk groups. Patients diagnosed with STEMI are 
always high risk, while those diagnosed with unstable angina are typically low risk. Patients diagnosed 
with NSTEMI can score anywhere within the range of risk scores, making them the most challenging of 
patients presenting with potential ACS. 
Although several risk-scoring systems have been developed, all have been shown to have some 
limitations (17,25). In cases of suspected ACS, not all patients show the characteristic ECG changes 
required for a clinical diagnosis of acute myocardial ischemia. For example, patients without ECG 
abnormalities but with symptoms of restricted blood flow to the heart could be experiencing NSTEMI or 
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UA. This makes the use of biomarkers even more critical as an assessment measure for heart attack 
(3,23).  
To date, the most important cardiac biomarker for assessing risk in ACS is 
troponin. Troponin comprises a complex of three regulatory proteins (troponin 
C, troponin I and troponin T) that interact to control the calcium-mediated 
interaction of actin and myosin that causes the contraction of striated muscle 
(i.e., skeletal and cardiac muscle). Unlike troponin C, the other two proteins, 
troponin I and T, take a unique form in cardiac muscle and are known as 
cardiac troponin I (cTnI) and cardiac troponin T (cTnT). When heart muscle cells 
have been damaged, cTnI and cTnT are released into the blood. The levels of 
these two proteins are measured to indicate the severity of damage that has 
occurred. Elevated levels typically indicate more severe damage (2).  
Cardiac troponins are considered the gold standard for diagnosing acute 
myocardial ischemia because they are a reliable indicator of heart damage (3,18). Troponin POCT has 
the potential to expedite the time to treatment in the ED by distinguishing low-risk patients from high-
risk patients. Troponin POCT is administered at the patient’s bedside, reducing the amount of time spent 
in the collection, transportation and processing involved in the more traditional central lab testing 
(21,26). Troponin POCT has become increasingly sensitive as the role of cardiac troponins in cardiac 
damage has become better understood and the technologies behind troponin POCT devices have 
improved3.  
 
What we looked for 
 
Searching for the Evidence 
The CHRSP methodology synthesizes research-based evidence from the systematic review literature, 
which includes systematic reviews, health technology assessments (HTAs) and meta-analyses. Recent, 
high-quality primary research studies that have not yet been captured by the systematic review 
literature are also included in the synthesis. We identified evidence by searching periodical indexes of 
published articles as well as databases of grey literature (i.e., not commercially published reports).4  The 
selection criteria for inclusion in the synthesis are summarized in Table 2 below. 
Article selection was carried out by two members of the CHRSP staff, with discrepancies resolved 
through discussion and, if needed, consultation with the Scientific Team Leader. 
                                                          
3
 See Online Companion Document, Performance Measurement for Troponin POCT, for more details. 
4
 See Online Companion Document, Project Search Methods, for more details. 
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Table 2: PICOS and article eligibility criteria 
Parameter Eligibility Criteria 
Population 
Include Study population is presenting with potential ACS, adult, human 
Exclude 
Study population has already been diagnosed with ACS or ACS has been previously 
ruled out 
Intervention 
Include 
Troponin POCT for suspected ACS is one of the interventions, or the only one, that is 
studied in a real-world setting 
Exclude Laboratory or real-world setting to determine diagnostic accuracy of troponin for ACS 
Comparator Include All comparators are eligible for inclusion 
Outcome Include All outcomes are eligible for inclusion 
Setting 
Include 
Emergency departments, intensive care units, or any other health care facilities that 
see emergency cases or patients presenting with potential ACS 
Exclude 
Emergency medical service settings involved in the transportation of patients, 
including ambulances and medevac services. 
Article 
Include 
Any publication with a systematic review or recent randomized controlled trial not 
captured in the systematic review literature, or any health economic primary 
research article/report. Any article/report published between 2003 and 2013 in any 
language. 
Exclude 
Any article/report that is a duplicate, based on a more detailed study that is already 
included in the synthesis. 
 
We included five systematic reviews that synthesized evidence from a total of 150 individual primary 
research studies. The systematic review literature had virtually no overlap in terms of the primary 
research that was synthesized, since 99.9% of the primary research studies were cited by only one 
systematic review. We included eight primary research studies that were not captured by any of the 
included systematic reviews. In addition to these articles and reports, we included seven health 
economics research articles and reports that studied troponin POCT.5  
Table 3: Summary of included studies  
Systematic Review Literature 
Study AMSTAR Study Type 
CADTH Optimal Use Report, 2012  73% Health Technology Assessment 
Lin, 2012 55% Systematic Review 
CADTH, 2012 45% Review of Systematic Reviews 
Storrow, 2009 45% Systematic Review 
Craig, 2004 36% Health Technology Assessment 
Primary Research Literature (health economic evidence not included) 
Study Downs & Black Study type 
Collinson, 2013 89% Point-of-care Arm of a Prospective Randomised Controlled Trial 
Renaud, 2008 89% Open-label, Randomized Single Center Trial 
Goodacre, 2011 82% Pragmatic Multicentre Randomised Controlled Trial 
Bradburn, 2012 75% Pragmatic Multicenter Randomised Controlled Trial  
Loten, 2009 75% Clustered Randomised Controlled Trial 
Collinson, 2011 75% Prospective Randomized Trial 
Ryan, 2009 71% Multicentre, Randomized Parallel Group Trial 
Morgensen, 2011 54% Randomised Clinical Trial 
                                                          
5
 See Online Companion Document, Project Search Results, for more details. 
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Assessing the Evidence 
For clinical outcomes and emergency department process outcomes, two CHRSP staff worked with the 
Project Team Scientific Leader to synthesize the evidence from: 
 two systematic reviews, Lin et al., 2012 and Storrow et al., 2009 (27,28);  
 two HTAs, CADTH, 2012-2013 and Craig et al., 2004 (29–32); and 
 one review of systematic reviews, CADTH, 2012 (33).  
For health economics outcomes, the CHRSP Project Team’s Health Economist assessed the articles, 
extracted the data and synthesized the evidence. 
Two CHRSP staff critically appraised the methodology of the included systematic review literature using 
the Assessment of Multiple Systematic Reviews (AMSTAR) which is an experimentally-validated 
instrument (1).6   It is important to point out that a low AMSTAR score does not necessarily mean that 
the review should be discarded; rather, a low score indicates that less confidence should be placed in 
the review’s findings and that the review must be examined closely to identify its strengths and 
limitations.  
Primary research literature was appraised using the Downs and Black tool (5). This appraisal tool 
provides a checklist to draw attention to a paper’s methodological strengths and weaknesses and is 
appropriate for randomised controlled trials as well as non-randomised studies or observational 
studies.7  See Table 3 above for critical appraisal scores. 
Discrepancies in scoring were resolved through discussion and, if required, through consultation with 
the Project Team Scientific Leader (NPP).  The inter-rater reliability (IRR) was measured with Cohen's 
Kappa8: 0.87 (95 CI: 0.97, 0.77) for AMSTAR and 0.75 (95 CI: 0.89, 0.61) for the Downs and Black.  Both 
these scores are considered to indicate “excellent inter-rater reliability” (34).  
Data Extraction, Synthesis and Contextualization 
For all but the health economic evidence, one CHRSP staff extracted the data from the included 
systematic reviews and primary research studies, while another CHRSP staff reviewed the work. Any 
disagreements identified upon review of the extracted data were discussed and resolved through 
discussion between the extractor and the reviewer. Any remaining discrepancies were resolved through 
consultation with the Project Scientific Leader. We extracted review findings from the systematic review 
literature, which we define as a conclusion that is based on a combination of primary research evidence. 
We extracted basic findings from the primary research literature that supplemented the review findings. 
The health economic evidence was sent to the Project Health Economist who extracted the data and 
conducted his own analysis. 
                                                          
6
 See Online Companion Document, Critical Appraisal, for more details. 
7
 See Online Companion Document, Critical Appraisal, for more details. 
8
 Cohen’s Kappa ranges from -1 to 1: 1 indicates complete agreement between raters; 0 is the level of agreement 
that would be expected if the ratings were selected at random; and -1 indicates complete inverse agreement 
between raters. 
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The results of the data extraction were grouped into different outcome categories, e.g., diagnostic 
accuracy and patient satisfaction, and formed the basis for the synthesis in this report. 9  A draft of the 
report was prepared by the Project Scientific Lead, the Project Health Economist and two CHRSP staff. 
The draft was then reviewed by the Project Team which was consulted on the contextualization of the 
findings.  External consultants were also contacted for additional contextualization.  
What we found 
Overview of the Evidence  
Point-of-care testing, in general, has been available since the early 1990s and is, at present, a rapidly 
developing field of medical research. Research-based evidence for POCT, in general, reflects ongoing 
advances in instrumentation, especially with increasing abilities in the detection of target biomarkers 
(35). Significant improvements in POCT may not be captured by the most recent review literature as it 
takes years to publish high-quality systematic reviews and meta-analyses.  
In the case of cardiac troponin POCT products in particular, there has been a rapid improvement in 
testing threshold sensitivity. New technologies are able to detect cardiac troponin with continually 
lower detection thresholds and more accurate detection capabilities resulting in a heterogeneous and 
changing state of POCT research protocols.  Authors have noted the challenges in finding comparable 
studies for cardiac troponin POCT meta-analyses (27,28,32,33,36). As a result, there are fewer 
systematic reviews than would be expected, despite the availability of considerable primary research.  
Table 4: Summary of design characteristics of included studies 
Systematic 
Reviews 
Population Settings Time Frame 
CADTH Optimal 
Use Report, 2012 
Average: 702.22 
Range: 94-1452 
EDs or Chest pain units Germany, 
New Zealand, United States, 
Canada, UK, France, Sweden.  
Studies published between 
2009-2012 
Lin, 2012 
Average/Range: Not available Not available Studies published between 
2004-2010 
CADTH, 2012 Apr 
Average/Range:  
No studies on Troponin found 
No studies on Troponin found No studies on Troponin found 
Storrow, 2009 
Average: 540 
Range: 33-2000 
Single ED to Multicentre Studies published between 
2001-2008 
Craig, 2004 
Average/Range:  
No SR, MA or HTA found. 
Details of other studies 
reviewed not identified. 
No SR, MA or HTA found. Details of 
other studies reviewed not 
identified. 
No SR, MA or HTA found. Details 
of other studies reviewed not 
identified. 
NB: Average and Range refer to the sample sizes of the included studies. 
  
                                                          
9
 See Online Companion Document, Data Extraction Results of Included Studies, for more details. 
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RCTs Population  Settings Time Frame 
Collinson, 2013 
2263 (2243) 
POCT =1132  (1125) 
Non POCT= 1131(1118) 
6 EDs  30 January 2007 and June 2008 
Renaud, 2008 
860 
POCT= 428 
CHLT=432 
Single ED November 2002 – April 2004 
Goodacre, 2011 
2243 
POCT=1125 
Standard Care=1118 
6 EDs January 30, 2007 – June 2, 2008 
Bradburn, 2012 
2243 
Range= 327-469 per ED 
6 EDs January 30, 2007 – June 2, 2008 
Loten, 2009 
1194 
POCT=467 
Lab Test=445 
2 EDs Eastern Australia John Hunter 
Hospital Belmont Hospital 
November 2007 to January 2008 
Collinson, 2011 
2263 recruited 
POCT=1125 
Non POCT=1131 
6 EDs 30 January 2007 and 2 June 
2008 
Ryan, 2009 
2134 recruited 
Range – 348-602 per site 
POCT =1000 
Central Lab= 1000 
4 EDs in the US Between December 2004 and 
November 2006, 
Morgensen, 2011 
239 
POCT= 109 
Central Lab = 120 
ED Kolding Sygehus, Denmark October-November 2009 & 
February 2010 – April 2010 
 
Several key issues have been highlighted in these reviews of troponin testing. The Canadian Agency for 
Drugs and Technologies (CADTH) in Canada has addressed the problem of a lack of review literature in 
several of its reports. CADTH has used a variety of reporting forms to investigate cardiac troponin POCT 
between 2007 and 2013. Report types range in comprehensiveness from Rapid Response Reports (these 
are essentially reference lists) to HTA-style Health Technology Inquiry Service reports.  CADTH found the 
lack of review literature on this topic to result from: narrowly defined research questions; primary 
research protocols with diverse study designs, outcome measurements or endpoints; and limited 
timeframes when searching for evidence (27–32,36–38). CADTH’s Optimal Use Report also identified a 
general lack of economic evaluation of cardiac troponin testing, which was one of the main motivations 
for their report (29–31).  
Some of our included studies had weaknesses in experimental design that could have introduced bias 
into the reported results. The study by Goodacre et al. (2011) was not sufficiently powered to detect 
potentially important differences in rates of adverse events (39), while the sample size in the study by 
Morgensen et al. (2011) lacked adequate power to detect anything but very large effect sizes (40). Lack 
of double blinding in the Bradburn et al. (2011) and Ryan et al. (2009) studies may have contributed to 
observer effects (41,42).  Authors in both the Collinson et al. (2013) (p. 35, 64) and Renaud et al. (2008) 
(p. 222) indicated that there was the potential for selection bias in their studies (17,23). We did not 
identify any attrition bias, reporting bias or potential performance bias (affecting delivery intervention 
because of a lack of single blinding). 
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Test Performance 
Test Performance refers to the ability of a test to differentiate between normal/healthy and 
abnormal/unhealthy states.  It is the first and most important outcome category when considering the 
effectiveness of a medical test.  In the context of this project, test performance refers to the ability of a 
cardiac troponin POCT to correctly distinguish patients who are positive for Acute Coronary Syndrome 
(ACS) from patients who present with similar clinical symptoms but who are negative for ACS.  POCT 
results are compared against a “gold standard test,” which, in this case, would be cardiac troponin 
tested by a central laboratory.  
Figure 3: Test performance matrix 
Test Outcome 
 
Condition  
(determined by gold standard) 
    
Test performance measures↓ 
Condition  
Positive 
Condition  
Negative 
Test  
Positive 
True  
Positive 
False  
Positive 
Precision = 
True Positive 
Test Positive 
Test 
Negative 
False  
Negative 
True  
Negative 
Negative Prediction Value = 
True Negative 
Test Negative 
Test 
performance 
measures→ 
Sensitivity* =  
True Positive 
Condition Positive 
Specificity =  
True Negative 
Condition Negative 
Accuracy = 
(True Positive + True Negative) 
Total Population 
* Sensitivity is more important than specificity when testing the performance of screening tests such as cardiac troponin POCT. 
Test performance is measured by ratios that combine the different test outcome groups: true positives, 
false positives, true negatives and false negatives. 
 Sensitivity is the ratio of true positives to all real positives.  
 Specificity is the ratio of true negatives to all real negatives.10  
Different medical tests make a trade-off between sensitivity and specificity, depending on their purpose:  
 Screening tests determine whether a patient should be further studied or discharged. These 
tests prioritize sensitivity over specificity to increase the likelihood of detecting patients with the 
condition at the expense of false positives (patients without the condition that test positive);  
 Diagnostic tests determine if a patient will receive a treatment. They prioritize specificity over 
sensitivity to rule out patients without the condition at the expense of false negatives.    
Cardiac troponin POCT is considered a screening test: sensitivity is of greater importance than 
specificity. 
                                                          
10
 See Online Companion Document, Performance Measurement for Troponin POCT, for more details. 
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Table 5: Sensitivity and specificity ranges for different cardiac troponin POCT products 
Study Analyzer Setting Sensitivity Specificity Notes 
Collinson, 
2013 (17) 
Stratus CS 
Admission, 
N=831 
0.803 
(0.687 to 
0.891) 
0.979 
(0.966 
to0.988) 
cTnI: detection limit 0.03 μg/l, analytical 
range 0.03–50 μg/l, interassay CV 4.0–
8.2% (0.067–0.344 μg/l), the 99th 
percentile of the assay is 0.07 μg/l Stratus CS 
Peak value, 
N=833 
0.955 
(0.875 to 
0.991) 
0.969 
(0.954 to 
0.980) 
CADTH 
Optimal 
Use Report, 
2012 (16) 
Roche 
Elecsys, 
Hs-cTnT 
N=1,098 
0.91 (0.87 
to 0.94) 
0.81 (0.80 
to 0.82) 
0.014 (99th percentile) 
Collinson, 
2011 (43) 
  
Stratus CS 
cTnI 
Admission 
N=1,074 
0.845 
(0.750 to 
0.915) 
0.976 
(0.964 to 
0.984) 
cTnI detection limit 0.03 mg/l, analytical 
range 0.03e50 mg/l, inter-assay 
coefficient of variation (CV) 4.0e8.2% 
(0.067e0.344 mg/l). 
The 99th percentile of the assay is 0.07 
mg/l. 
Stratus CS 
cTnI 
90 min 
N=844 
0.941 
(0.713 to 
0.999) 
0.984 
(0.973 to 
0.992) 
Stratus CS 
cTnI 
Peak value 
plus change, 
N=1,078 
0.976 
(0.918 to 
0.997) 
0.963 
(0.949 to 
0.974) 
  Takhshid, 
  2010 (44) 
Vidas  
Admission 
N = 123 
42%  
(28%-55%) 
100% 
(92%-
100%) 
Limit of detection <0.01 µg/l; 10% total 
imprecision concentration determined 
over 20 days using 2 kit lots and 2 
calibrations per lot in 3 systems was 0.11 
µg/l; and total imprecision (n=244) for 
quality control materials with 
concentrations at 0.58 µg/l were 3.3% and 
3.4% respectively. A cTnI value ≥0.01 µg/l 
was suggestive of AMI 
Findings not established by the authors, 
but by the manufacturer. 
  Meek,  
  2012 (45) 
Biosite 
Admission 
N=248 
92.6% 
(74.2-98.7)  
98.7% 
(95.9-99.7)  
 
For cTnI: limit of detection 0.05 ng/mL and 
99th percentile 0.05 ng/mL 
  Stengaard 
  2013 (46) 
Cobas 
h232 
Admission 
(ambulance) 
N = 990 
39 (32 -46) 95 (94-97) Not reported  
  Wu, 
  2004 (47) 
RAMP 
Admission  
N = 365 
90  
(80 – 99) 
86 (78 – 
94) 
The lower limit of detection was 0.03 
ng/ml (10% coefficient of variance [CV] = 
0.21 ng/ml) for cTnI 
The upper reference limit (normal range) 
was < 0.03 ng/ml for cTnI 
  Apple,  
  2004 (48) 
I-Stat 
Admission 
N = 186 
Not 
reported 
Not 
reported 
Total imprecision (CV) of 10% and 20% 
were seen at 0.09 and 0.07 µg/l, 
respectively. The detection limit was 0.02 
µg/l. The 99th percentile reference limit 
was 0.08 g/l. 
  Apple,  
  2009 (35) PathFast Not reported 
Not 
reported 
Not 
reported 
99th percentile µg/L = 0.029 
10% CV, µg/L = 0.014 
Based on manufacturer claims. 
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The Health Technology Assessment by Craig et al. (2004) compared cardiac troponin POCT to traditional 
lab testing. This very comprehensive HTA is synthesized primary research from prior to 2002.  At the 
time of writing, troponin POCT devices existed in both qualitative and quantitative designs.  The Craig et 
al. HTA found that troponin POCT and central lab testing techniques differed significantly in terms of 
quality control.  Most of the devices at that time, for either quantitative or qualitative design, did not 
meet the established criterion that has become the standard for POCT, i.e., detection of the biomarker 
with no greater than 10% coefficient of variation (CV) at the 99th percentile of the biomarker 
distribution for a reference population (see Online Companion Document for more details) (32). 
Unfortunately, as troponin assays became more sensitive and could measure at lower concentrations, 
many of these newer troponin assays could not achieve a 10% CV at the 99th percentile.   
However, as described in the previous section, the development of cardiac troponin POCT technologies 
has been continuous and significant (see Table 5 above). Storrow et al. (2009) observe that POCT in 
general, and cardiac troponin POCT in particular, have “dramatically improved” in accuracy over the past 
decade (28).  Recent primary research has demonstrated that, as a screening test, cardiac troponin 
POCT is a comparable and reliable alternative to lab testing:  
 One primary study compared POCT for cardiac troponin and two additional cardiac analytes to a 
local lab protocol for cardiac troponin and found that POCT for “[cardiac] troponin alone is 
sufficient for early diagnosis and exclusion of AMI and can be reliably measured by point-of care 
testing within [two hours] if the method can define the 99th percentile” (43) 
 Further analysis of the same POCT data by Collinson and colleagues published in 2013 found 
that measurements of cardiac troponin taken on admission and then again at 90 minutes 
enabled a low risk group of patients to be successfully discharged (17).   
The main development in cardiac troponin POCT design is the ability to detect ever lower concentrations 
of the analyte in blood samples. A new class of cardiac troponin POCT is called the high sensitivity assay. 
There is some independent research-based evidence that high sensitivity POCT troponin testing can 
provide results more quickly (i.e. at lower troponin concentrations than ‘regular’ troponin POCT at 
comparable levels of accuracy to central lab testing).  
In comparing the two tests, CADTH found that high-sensitivity cardiac troponin T (the hs-cTnT POCT) was 
more accurate than regular cardiac troponin I (cTnI POCT).  Using a cut-off point of the 99th percentile 
values for a reference population, the sensitivity and specificity findings were as follows: 
 Sensitivity for the hs-cTnT POCT for diagnosis of AMI were found to be 0.91 (95% CI, 0.87 to 
0.94) and specificity was 0.81 (95% CI, 0.80 to 0.82); 
 Sensitivity for cTnI POCT was found to be significantly lower (0.62, 95% CI, 0.58 to 0.66), while 
the specificity was slightly higher (0.96; 95% CI, 0.94 to 0.97) (29–31).  
This indicates that hs-cTnT is a better screening test than cTnI.  
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Recently, Trinity Biotech of Ireland announced that it has received European approval for a high-
sensitivity cardiac troponin I point-of-care diagnostic test.  FDA approval in the US is pending (49). 
Key Message: 
In terms of test performance, the sensitivity and specificity of currently available 
cardiac troponin point-of-care tests are sufficient for their use as screening tests.  
Cardiac troponin POCT continues to improve at a significant rate and is becoming  
as accurate as central lab testing.  
(Effective Intervention) 
Clinical Health Outcomes 
Clinical health outcomes are related to the patient’s health after a cardiac troponin POCT in an 
emergency department setting.  Such outcomes would include subsequent adverse cardiovascular-
related events and readmission to hospital.  Although the available evidence base is neither extensive 
nor highly-powered, the evidence does indicate that cardiac troponin point-of-care tests provide similar 
clinical health outcomes to those of central lab testing. 
Goodacre et al. (2011) found a very low adverse cardiovascular-related event rate for patients who 
received troponin POCT (1/5) and no significant difference in adverse events between the POCT patients 
and control groups (39).  Among patients who were discharged, only one out of the five adverse events 
under study occurred within one month of recruitment.  In contrast, four out of five adverse events 
occurred among patients who were admitted to hospital (i.e., who were correctly identified as being at 
high risk.)  As a note of caution, the authors indicated that the trial was not sufficiently powered to 
generalize these differences. 
Collinson et al. (2011) reported that, compared to patients who were tested by the central lab, POCT did 
not increase major adverse coronary events including death, readmission or the need for 
revascularization within three months of the test.  In 2013, Collinson et al. concluded that there was no 
difference in adverse events between patients tested with POCT and those tested via ‘conventional 
management’ (17,43). 
CADTH’s Optimal Use Report sought to find evidence on the effects of cTn tests on readmission rates; 
however, these were not reported in any of the included studies (29–31).  
Key Message: 
In terms of clinical outcomes, cardiac troponin POCT does not appear to increase 
the risk of adverse cardiac-related events or readmission rates compared to central 
lab testing for patients seen in emergency departments.  
(Promising Intervention) 
  
NLCAHR October 2014 Troponin Point-of-Care Testing in Emergency Departments in Newfoundland 
and Labrador 
33 
Emergency Department Process Outcomes 
This category of outcomes measures the efficiency of POCT in an emergency department setting. To 
make these measurements, efficiency variables are grouped together to help ascertain the resources 
required to achieve a given outcome.   For this project, the evidence on emergency department process 
outcomes, or efficiency, was mainly limited to studies that looked at the length of time taken for 
patients to achieve a particular endpoint. The range of possible endpoints, combined with the variability 
in definitions for each endpoint produces a great deal of heterogeneity among primary research study 
results.  This, in turn, makes it challenging for systematic review studies to synthesize the available 
evidence.    
Following are some of the emergency department process outcomes of concern to decision makers 
when considering cardiac troponin point-of-care testing. 
Turnaround Time 
Turnaround time (TAT) is the time elapsed between taking a blood sample from a patient and reporting 
the results of that sample. The most consistent and important synthesis finding in this project is that 
cardiac troponin POCT significantly reduces TAT compared to lab testing (28,42). Ryan et al. (2009) 
found that central lab testing for cardiac troponin took an average of 58 minutes (IQR 44 to 81 minutes)  
compared to 15 minutes (IQR 11 to 23 minutes) for POCT.  Storrow and colleagues state unequivocally 
that “improvements in TAT are nearly universal” (28). 
Key Message: 
When compared to central lab testing, emergency department cardiac troponin 
point-of-care tests significantly and consistently reduce turnaround time for test 
results.  
(Effective Intervention) 
Time to Decision, Time to Disposition, Time to Treatment, Time to Transfer  
These outcomes include measures of the time elapsed between the arrival of the patient at the care 
facility and a key decision being made or an action being taken.  Beginning from various starting points 
(including the time the patient registered at the emergency department or the time the triage result was 
recorded), these outcomes include:  
 Time to Decision: the elapsed time until a clinical decision is recorded about the treatment plan;  
 Time to Disposition: the elapsed time until the decision to admit or discharge the patient is 
recorded; 
 Time to Treatment: the elapsed time until a treatment is administered; and 
 Time to Transfer: the elapsed time until a patient is transferred to another unit for care. 
It is logical to assume that the consistent and significant improvement in turn-around time for the 
cardiac troponin POCT (as noted above) would have a subsequent effect on improving these time 
outcomes. 
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Some evidence does support this assumption.  For example, Renaud found that the Time to 
Decision/clinical decision making process was shorter when POCT was used, as compared to using a 
central lab test.  In a subset of patients suspected of being high-risk and having NSTEMI, POCT shortened 
the time to anti-ischemic therapy (TAIT) by nearly 40%. The median TAIT for POCT was 151 min (IQR 
=139-162 min) compared 198 min for central lab testing (IQR 187-210 min). An important corollary to 
this finding was that patients with vague symptoms were diagnosed sooner (23). 
However, the available evidence on Time to Decision is not consistent.  CADTH’s Optimal Use Report 
could not find any eligible evidence to support a claim of improved Time to Decision: “No description 
related to ED times between the performance of cardiac troponin [POCT] tests and the diagnosis of MI 
or ACS was found in the included studies”p23 (29).  
Furthermore, Storrow et al. (2009) could not confirm reduced Time to Treatment after a cardiac 
troponin POCT, but stated that the data suggested improvements in this area were possible (28).  
These findings imply that factors other than test turnaround time influence the amount of time it takes 
to decide on the course of action for patients suspected of ACS and then to act on that decision. The 
effectiveness of POCT for improving these time outcomes appears to be mediated by those factors.  
Length of Stay/Time to Discharge 
Length of Stay (LOS) and Time to Discharge are outcomes that measure the overall elapsed time for a 
patient’s visit to the emergency department.  As with the time outcome measures described above, 
although the evidence consistently indicates that cardiac troponin POCT reduces turnaround time, this 
improvement does not necessarily result in consistent improvements in measures of the overall elapsed 
time spent in the emergency department:  
 The systematic review by Storrow et al. could not find consistent improvements in LOS or Time 
to Discharge between POCT and central lab cardiac troponin testing (28).  
 The RATPAC study found a reduction in the median, but not the mean LOS in the emergency 
department with troponin POCT compared to central lab testing (39,41).  
 Renaud and colleagues found that troponin POCT did not demonstrate a significant difference in 
emergency department LOS compared to central lab methods (23).  
 Loten and colleagues report an improvement of 48 minutes (approximately 10%), which they 
claim is an underestimate of the true improvement in patient emergency department LOS (50). 
One explanation for these conflicting results is that, apart from affecting test turnaround time, cardiac 
troponin testing methods are not the determining factor for Emergency Department Process Outcomes 
(Bradburn, 2011; Storrow, 2009; Renaud, 2008, Ryan, 2009). Site-specific variables such as the individual 
facilities themselves, local protocols, existing and implemented guidelines for ACS and related 
symptoms, existing POCT and central lab cardiac troponin tests and staffing variables, appear to explain 
“the variation in outcomes and costs” (41). Renaud and colleagues cite the need for a whole-system 
approach to maximize timeliness of care (23). Ryan and colleagues (2009) also found the same, 
concluding:  
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Although our findings suggest that at some institutions point-of-care testing makes a 
difference, there is still a wide range of effects… In conclusion, the effect of point-of-care 
testing on length of stay in the ED varies between settings. At one site, point-of-care 
testing decreased time to admission, whereas at another, point-of- care testing 
increased time to discharge. Potential effects of point-of-care testing on patient 
throughput should be considered in the full context of ED operations.(42) 
Key Message: 
Cardiac troponin POCT appears to have the capacity to reduce emergency 
department process time outcomes compared to central lab testing, but it cannot 
achieve those outcomes by itself.  Other site-specific variables appear to have an 
equal or greater impact on those outcomes. Point-of-care testing must be 
considered in the full context of emergency department operations for improvements 
in patient throughput to be truly quantified. 
Cardiac Troponin POCT in Small Hospitals 
The evidence reviewed so far compares testing with cardiac troponin POCT to testing carried out in open 
and operating central labs.   In Newfoundland and Labrador, many facilities do not have access to 24/7 
open and operating central lab services at the time when the troponin test is needed; therefore, a more 
meaningful comparison might be between the effects of POCT on test performance, clinical health 
outcomes and emergency department process outcomes when compared to call-back or no central lab 
testing whatsoever.  
Little current research makes this direct comparison.  However, we located one primary research study 
by Loten and colleagues that does include this assessment.  In their multi-site RCT studying emergency 
department cardiac troponin POCT on length of stay, they included one facility that did not have a 24/7 
central lab.  Not surprisingly, they found that POCT had the greatest impact at that particular facility: 
“[a]s expected, the difference [LOS] was more marked at the site where pathology was not available 
around the clock; it is in these situations when the most potential gains could be made” (emphasis 
added). This study clearly indicates that those sites where central lab facilities are not available 24 hours 
a day could see the greatest improvements in terms of emergency department process outcomes such 
as length of stay (50).  
Key Message: 
Point-of-care testing has the greatest impact on emergency department process 
outcomes in facilities without a 24/7 central lab service. 
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Health Economic Evidence 
 
Overview of the Health Economic Evidence 
The health economic evidence for cardiac POCT in the emergency department is based on nine articles 
(see Table 7 below).  Among those, six present the findings of economic analyses (cost minimization or 
cost-per-unit of outcome) comparing a bedside (POCT) strategy to a central (hospital or reference) lab 
strategy (32,41,51–54).  
Three articles offer separate descriptive analyses of the costs and some of the benefits of POCT relative 
to standard assessment without making any attempt to calculate a cost-efficiency ratio (55–57). 
However, these documents do shed light on some of the issues discussed in the economic analyses 
(56,57) or provide point estimates of prices in one setting (32,55).11  
The following four studies describe a comparison between POCT and central lab testing within the same 
hospital: 
 Craig et al. the HTA for the NHS in Scotland;  
 Fitzgerald et al. for a study of the RATPAC trial in the UK 
 Bradburn et al. for a study of the RATPAC trial in the UK 
 Birkhahn et al. for a non-blinded RCT in one institution in the US) (32,41,51,53)  
Craig et al. conducted a cost-minimization analysis asking whether, even though the average cost of one 
bedside test is higher, decreased costs from reduced turnaround times offset the difference in 
administration costs between the two strategies.  Bradburn et al., Birkhahn et al. and Fitzgerald et al. 
run cost-utility analyses, with patient-hours saved (41,51) and QALY (53) as their outcome measures.  
Table 6: Summary of included and excluded health economic evidence 
Included Studies: Health Economic Evidence 
Citation Source Type Measure 
Birkhahn et al, 2011  CRD POCT vs CL, cost-utility Patient hours (time in ED) 
Blattner et al, 2010  EMB POCT vs no lab, cost-effectiveness Cost benefits 
Bradburn et al, 2012  CRD POCT vs CL, cost-utility Patient hours (discharge) 
Craig et al, 2004  GLS BS vs CL, cost-minimization Multiple 
Fitzgerald et al, 2011  CRD POCT vs CL, cost-utility QALY 
Fitzgibbon et al, 2010  CIN Survey of devices Comparison of device price 
Hortin, 2005 GS Multiple cost perspectives of POCT  Costs per treatment 
Lewandrowski, 2009  EMB General comment n/a 
Van Dyck et al, 2012  CRD Micro-simulation, cost-utility QALY 
  
                                                          
11
 Craig et al., 2004 also provides a point estimate of prices in the Scottish NHS. 
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Table 6 continued… 
Excluded Studies 
Citation Source Reason for Exclusion 
Amsterdam et al, 2010  EMB No economic evidence  
Asassi et al., CADTH, 2013  GLS Not POCT vs Central Lab 
CADTH, 2012a  CRD No studies measured cost 
CADTH, 2012b  GLS No economic evidence 
CIMON/CADTH, 2007  GLS No economic evidence 
Collinson et al, 2013  GLS Not POCT vs Central Lab 
Goodacre et al, 2013 GS Not POCT vs Central Lab 
Goodacre, 2010  CIN Same as Fitzgerald et al. 2011 
Source abbreviations: CRD: Centre for Reviews Dissemination Database; EMB: Embase Biomedical Database; GLS: Grey Lit Search (see Online 
Companion Document); CIN: CINAHL Database; GS: Google Scholar. 
 
The study by Blattner et al. was set in one hospital and one health district in New Zealand. It describes 
the effect of implementing bedside testing in a remote hospital with no lab facility. The choice prior to 
POCT availability in this hospital was between clinical assessment only and sending a sample to the 
nearest hospital, situated at a driving distance of two hours. POCT allowed emergency department 
physicians to enhance their diagnosis, disposition planning, and treatment decisions relative to clinical 
assessment alone and this has consequences on patient-care costs (i.e., fewer unnecessary admissions). 
POCT was more expensive than clinical assessment alone, but the aim of the cost-effectiveness study 
(cost-minimization) was to measure patient-care expenditures saved against the cost of implementing 
POCT in the remote hospital (52).  
Lastly, Van Dyck et al. carried out a micro-simulation of the treatment chain of patients with chest pain. 
Patients could either go to the emergency department and receive standard care or visit a primary care 
physician equipped with POCT.  The primary care physician could:  
 diagnose the patient as having stable angina and prescribe appropriate medication;  
 diagnose the patient as being free from ACS; or  
 diagnose the patient as having unstable angina or AMI and refer them to an emergency 
department.  
The study was run as a cost-utility analysis, with QALY as their outcome measure (54). 
Overall Costs of ED Cardiac Troponin POCT 
The main reason POCT is more expensive than central lab testing is the increased cost of the reagent 
slides or cartridges for POCT compared to the lower cost for central laboratory tests.  This cost factor is 
compounded by the fact that each POCT quality control measurement will consume a new slide or 
cartridge (56,57).  A central lab spreads its fixed costs for quality control over more tests, thereby 
reducing the average cost per test.  However, the higher cost of POCT is highly conditional on its degree 
of connectivity and integration with central electronic management systems.  As electronic quality 
controls (e-QC) are increasingly incorporated into POCT devices, bedside testing is predicted to cost less 
and eventually approach the same costs as central lab tests (57,58).  A secondary reason why POCT has 
higher costs is that bedside clinicians are not trained to read test results and therefore require training, 
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whereas lab personnel do not.12 Craig el al. found that point-of-care tests were 2.5 times more 
expensive per test than central lab testing in the Scottish NHS before 2004 (32). 
A paper by Hortin raises the issue that an important (but unnoticed and unaccounted) source of cost for 
central lab testing of cardiac troponin is the time spent collecting, reading, and, in the case of central lab 
testing, sending samples to, waiting for and collecting back results.13  The author claims that nurses 
spend much more time interacting with the central lab than performing the tests themselves at the 
bedside (56).  
Fitzgerald et al. carried out a micro-costing study of 246 patients (124 in the control group and 122 in 
the POCT group). They estimated an increased emergency department cost for POCT of USD 83 on 
average per patient compared to standard treatment (2007/08 prices).  The increased cost came from 
greater staff cost (USD 18, 22%), cost for the POCT test itself to the emergency department14 (USD 60, 
72%), and overhead costs to the emergency department (USD 5, 6%). Additional details of their work are 
included in a supplementary table from their publication, reproduced as Table 7 below. They accounted 
also for calibration costs of the device (around USD 2,200) and panel costs (USD 32 per panel) but not 
for the purchasing cost of the device or connectivity costs (53). 
Table 7: Detailed unit costs for troponin POCT, Fitzgerald et al. (2011) 
Data Supplement 3 
Supplementary Table 3: Point-of-care testing unit costs 
Cost component Cost, £($) 
Panel costs (includes reagent, machine, and maintenance)  
Based on 1,500 full panels* 20.54 (32.06) 
Based on 3,000 full panels* 15.70 (24.51) 
Based on 3,000 troponin only panels* 5.70 (8.90) 
Calibration and quality control for full panel (per annum)** 1,426 (2,225.78) 
Calibration and quality control for troponin only panel (per annum)** 1,397 (2,180.52) 
*Costs provided by Hilda Crockett, Marketing Manager Point of Care, Siemens Healthcare Diagnostics 
**Based on 5 minute daily systems check, twice weekly 15 minutes quality control check and 5 min per reagent 
calibration check every 60 days, and Agenda for Change Grade 6 staff members (£29 per hour) 
 
The study also found that, beyond the emergency department, patients in the POCT arm spent more 
days in intensive care and cardiac care units (difference in cost: USD 208) and had more expensive 
interventions (difference in cost: USD 90). Patients in the POCT arm were less costly on lab tests and 
some other items.  Overall, patients in the POCT arm cost, on average, USD 320 more than patients in 
the standard treatment arm (53). This is the only micro-costing study available for ED cardiac troponin 
POCT.  
                                                          
12
 Although Hortin also seems to indicate that this is mainly the case for qualitative testing; this cost does not apply 
or apply as much to the cost of quantitative tests like the current forms of troponin POCT (56). 
13
 Rather, most studies assume that the elapsed time between collecting samples and receiving results is the same 
in the POCT and central lab testing arms, and therefore they do not bother to measure the time difference as a 
cost. 
14
 No cost to the central lab was factored in to the analysis. 
NLCAHR October 2014 Troponin Point-of-Care Testing in Emergency Departments in Newfoundland 
and Labrador 
39 
Birkhahn et al. do not have any data on the cost of emergency department cardiac troponin POCT 
compared to standard care. They assume USD 20 per individual POCT (versus USD 7 per test in standard 
treatment). The paper does not calculate per-patient costs, but rather a cost-per-unit of outcome, in this 
case patient-hours in the emergency department. The cost per-patient can be inferred from the study as 
being approximately USD 46, which is less than the cost estimate reported by Fitzgerald et al. (201) from 
the RATPAC study above (51).  
Van Dyck et al. carried out a micro-simulation and used a cost for cardiac troponin POCT of 
approximately USD 1,120, provided by a survey conducted by the Medicines and Healthcare Products 
Regulatory Agency in the UK (54). This is a much larger unit estimate than the USD46 used by Birkhahn 
et al. (51). Van Dyck and colleagues also calculates a net cost of POCT factoring in inpatient care; they 
estimate additional costs of EUR 480, a figure that is similar to the RATPAC estimate. However, based on 
the incremental ratios reported in the article (Incremental Net Monetary Cost and Incremental Health 
Benefit), the difference between POCT costs and standard care should be a savings of EUR 480 (54).  
A paper by Blattner et al. reports that the total cost of implementing POCT for six months in a remote 
hospital in New Zealand is NZD 50,000. This includes a high proportion of fixed costs as well as the 
individual test materials themselves (52). 
Economic Benefits of Cardiac Troponin POCT 
The greatest measured benefit so far from cardiac troponin POCT has been in reduced turnaround time 
(TAT). This may save unnecessary admissions to a medical or cardiologic ward, thereby saving costs to 
the payer (insurer or patient) and/or better throughput, i.e., allowing the hospital to see more patients.  
In the earliest study included in this health economic analysis, Craig et al. found that the main 
determinant of cost-savings via a reduction in TAT was not related to whether the test was performed at 
the bedside or in a central lab, but rather whether the central lab operated 24/7 and whether it worked 
continuously or by batch. A 24/7 continuously functioning central lab was as cost-effective as bedside 
testing, but a lab working only on weekdays and not after hours was more expensive, and more 
expensive still if working in batches (GBP 141 more per patient than POCT) (12). 
The Craig et al. HTA also found that a two-test cardiac troponin POCT strategy, at presentation and at 
10-12 hours, had the potential to reduce costs relative to central lab single-test methods. The two-test 
strategy reduced costs among patients who were appropriately given medications during the interim 
(12). However, the cardiac troponin POCT two-test strategy was shown to be more expensive than the 
lab two-test strategy (12). 
Birkhahn et al. found that using cardiac troponin POCT allowed the ED to admit or send patients home 
more rapidly. As a result, the ED was able to process more patients in a given period of time. On 
average, using the POCT assay saved 6.5 hours in the ED per patient (two hours due to bedside use and 
four and a half hours due to the use of myoglobin) (51). Bradburn et al. (based on RATPAC) did not find 
any clear effect, and concluded that outcomes were highly setting-dependent (41). Blattner et al. found 
savings from implementing bedside testing in a remote hospital, but the comparator was a situation 
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where physicians used clinical assessment only (with no biomedical testing at all) and, therefore, 
hospitalized too often (52). 
Two studies used quality-adjusted life years (QALYs) as an outcome measure. Van Dyck et al. and 
Fitzgerald et al. compared the gain in QALY resulting from receiving POCT to the gain in QALY from 
receiving standard treatment. The former study found a gain of 0.006 QALY from being in the POCT arm 
as compared to the standard arm (54). However, the POCT arm was in a primary care setting, and the 
link between the gain in QALYs and the use of POCT was not explained. Fitzgerald et al. further call these 
meagre results into question, finding the POCT arm resulted in a loss of 0.003 QALY compared to 
standard treatment (53). 
Summary 
The available health economics evidence is limited by the number of studies that have been published, 
as well as by a diversity of research methods that make comparisons difficult. These limitations add to 
the difficulties in drawing clear conclusions about the cost effectiveness of emergency department 
cardiac troponin POCT. 
All six included studies did agree that using cardiac troponin POCT is more expensive per patient than 
standard central lab testing (32,41,51–54). The increase in costs is because of increased fixed-costs for 
quality control and training. The reported evidence on the difference in costs ranges greatly and appears 
to be unreliable.  
The only situation in which there was evidence that the cost of POCT can be offset by monetary gains on 
post-testing treatment (i.e., inpatient cardiologic or intensive care) is the case of a remote hospital 
without any in-hospital testing alternative. In this case, the comparator was not central lab testing but 
clinical assessment with no quantitative testing (52). While this scenario is highly relevant to the current 
project, the different setting and jurisdiction, the single site and small sample size of the evidence 
compel a high level of caution in terms of generalizing the findings to Newfoundland and Labrador. 
The evidence for cardiac troponin POCT cost per patient-hour saved in the ED suggests a moderate cost 
(51) but it must be kept in mind that this is an estimated cost and not a measured cost. Craig et al. 2004 
have shown that a 24/7 central lab can save as many patient-hours as bedside testing (12).  
The RATPAC study finds that using cardiac troponin POCT is heavily dependent on setting. Overall, that 
study found POCT to be costly and to not improve quality of life. However, they do not consider patient-
hours saved in the ER as a possible benefit. Ultimately, the authors conclude that POCT is not a good 
strategy. Lastly, a micro-simulation of implementing POCT in family medicine practices is difficult to 
interpret, as it could generate a prohibitive cost per QALY or a societal benefit (41). 
Key Message: 
The evidence for the overall cost benefits of emergency department cardiac 
troponin POCT is incomplete and inconsistent.  The findings on the overall cost 
benefits are not conclusive. 
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The Newfoundland and Labrador Context 
 
The Contextualized Health Research Synthesis Program (CHRSP) interprets all project 
findings in consideration of the existing or expected circumstances of the province of 
Newfoundland and Labrador— a process known as contextualization.  Most research 
evidence synthesized in a CHRSP report has been generated in places that are 
considerably different from our province in any number of ways.  As a result, it may 
be the case that the research results cannot be directly applied here. We refer to 
‘contextual factors’ as the local conditions, capacities and qualities that may have an 
impact on the reported effects of our included research evidence.   
A contextual factor has the potential to enhance or to reduce the reported effectiveness, feasibility or 
acceptability of an intervention.15  We identify and assess contextual factors through the analysis of local 
data and research evidence16 as well as through interviews with local key informants that include local 
decision makers, administrators, front-line workers and stakeholder group representatives.  
In some rare cases, we do find research that has studied the effects of one or more contextual factors. 
For the POCT CHRSP Project, the available research evidence indicated that contextual factors at the 
level of the organization of the emergency department and testing services did have a significant impact 
on measured outcomes (see below).  However, most potential contextual factors were not adequately 
addressed in the available research evidence.  As a result, we can only estimate the potential effects of 
those contextual factors.  
Patient-Level Factors 
Patient-level contextual factors include demographic trends in the province, geographic considerations 
(i.e., where people live) and cultural features of the population. Our consultants identified several 
patient-level contextual factors that merit consideration when making decisions about implementing 
emergency department cardiac troponin POCT.  
Risk factors for ACS in rural and remote Newfoundland and Labrador:  The first patient-level 
contextual factor is the existence of higher risk factor rates for ACS among people living in rural and 
remote parts of the province where hospitals and health centres would be most likely to use emergency 
department cardiac troponin POCT located (e.g., without 24/7 lab services and callback lab services or 
without callback services at all). 
The root cause of ACS is arterial blockage and inflammation arising from atherosclerosis, which has the 
following risk factors: older age (45 for men, 55 for women), high blood pressure, high blood 
                                                          
15
 See http://www.nlcahr.mun.ca/CHRSP/CHRSP_CONTEXT_IN_DETAIL.pdf for more detail on contextualization in 
CHRSP projects. 
16
 The project originally intended to include health informatics data on ED lab requests, but was not able to obtain 
all the data necessary for the analysis. See Online Companion Document, Data Request. 
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cholesterol, tobacco smoking, lack of physical activity and Type II Diabetes (59,60). All these risk factors 
tend to be over-represented in rural areas of North America in general, and in Newfoundland and 
Labrador in particular (61–65).  Our consultants expected the increased rate of these risk factors to 
contribute to a higher incidence of patients presenting with potential ACS compared to national or even 
provincial rates.  This factor would enhance the cost effectiveness of troponin POCT at the emergency 
department level as fewer lab technicians would be called back.  
Patient transfers and monitoring:  Our consultants reported that, in the 
past, emergency department patients presenting with ACS or angina 
symptoms would sometimes decline an ambulance  transfer to another 
hospital with 24/7 lab services, opting instead to go home and return to 
the local hospital when lab services resumed the following morning.  A 
POCT cardiac troponin screening test delivered on site would be able to 
differentiate NSTEMI ACS patients who require closer monitoring (and possible transfer) from those with 
angina who could potentially go home more safely for the night, thereby decreasing the chances of 
someone in the higher-risk NSTEMI ACS group being released inadvertently.  The quicker turnaround 
time for POCT might also prevent delays in treatment and their resulting negative health consequences.  
Patient acceptance: Our consultants also reported that patients and their caregivers are very likely to 
accept an emergency department troponin POCT as an alternative to central lab testing after hours. This 
high level of acceptance and low likelihood for rejection of a new testing system may enhance, or at the 
very least not detract from, the reported effectiveness of emergency department cardiac troponin 
POCT. 
Design of Service Factors 
Our consultants identified a number of contextual factors at the level of the design of service for 
emergency department troponin POCT.   These factors mainly take into account the testing capacities of 
different types of Category B hospital emergency departments: those with 24/7 lab services (e.g., 
Carbonear General Hospital), those with lab callback services for after-hours testing (e.g., Old Perlican), 
and those without callback (e.g., Whitbourne).  
Advantages of POCT for sites where no callback is available: Emergency department troponin 
POCT is expected to be the most advantageous in the health centres/hospitals that do not have any 
callback for lab services.  Without emergency department troponin POCT, decisions about patients with 
possible ACS are made with incomplete information and a greater potential for error.  Only one primary 
research study in our synthesis explicitly included a hospital without any callback services and found the 
clinical effectiveness, efficiency and cost effectiveness to be significantly improved (50).   
Potential advantages for sites where callback is available:   Our consultants also advised that even 
those sites that have callback lab services might be expected to have enhanced outcomes with 
emergency department troponin POCT.  In some cases, attending physicians may not follow best 
practices in an effort to avoid lab technician callback because of the disruption, time commitment, and 
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associated costs of doing so.  In these instances, the convenience of POCT availability might be expected 
to promote clinical effectiveness and efficiency in testing. 
Potential risk of POCT misuse:    Our consultants informed us that there are ways in which the 
effectiveness of emergency department cardiac troponin POCT could be undermined in hospitals in 
Newfoundland and Labrador.  
 First, there is the potential risk that the cardiac troponin POCT device could be misused over 
time as a diagnostic test instead of a screening test.  Staff at smaller hospitals working after-
hours may start to consider an emergency department troponin POCT result as definitive, 
thereby increasing the likelihood of false positive results.  
 Secondly, staff at any hospital may begin to substitute the more convenient and cheaper POCT 
for the more sensitive, costly and time-consuming lab test, again increasing the likelihood of 
false positive results.  
 A third scenario that may present problems is the potential for confusion in distinguishing the 
results of a POCT screening test and those of a central lab diagnostic test.   
These risks, while not specific to the province, are cause for legitimate concern. Our consultants did 
indicate, though, that the province’s new system of accreditation (see below) and quality assurance 
measures, including protocols for use, are intended to prevent such misuse or misinterpretation.  
Design of emergency department workspaces: A separate 
contextual factor concerning design of service is the physical layout of 
the emergency department workspace. Our consultants pointed out 
that many smaller hospitals and nursing stations have only one nurse 
present afterhours. As a result, the emergency department cardiac 
troponin POCT would need to be within close range of the nurse so 
that it can be accessed without leaving the patient unattended.  Based 
on our consultations, it seems that most, if not all, facilities in the province have adequate and 
appropriate storage space to accommodate a troponin POCT in the emergency department. The POCT 
would also need to be designed in such a way that a single person could prep and administer the test 
relatively easily, since it is often the case that patients with ACS need physical assistance.  
Health Human Resource Factors 
In all emergency medicine settings in Newfoundland and Labrador, once the accreditation process has 
been completed, physicians will be responsible for ordering cardiac troponin POCT.17   
Physician Confidence: Our consultants indicated that it would be critical for emergency department 
physicians to have confidence in the reliability and accuracy of troponin POCT testing in order to 
effectively implement the test.  Without such acceptance, physicians will be less likely to request a 
cardiac troponin POCT in the emergency department. As a result, the cost-effectiveness of the test 
would be expected to decrease; the clinical effectiveness may decrease as well if the test is not used as 
                                                          
17
 In remote Labrador Community Clinics, physicians order tests via a live telehealth link. 
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often as it should be to maintain skills and competency (50). The province’s regional health authorities 
have a validation process in place for new biomedical tests that is intended and designed, in part, to 
demonstrate the reliability and accuracy of new tests to 
physicians. 
Nurse Training:  While physicians will be responsible for ordering 
the test, emergency department nurses will be responsible for 
administering it.  Nurses have traditionally administered bedside 
testing, (e.g., glucometers or urinalysis) and our consultants 
expected they would consider troponin testing professionally 
acceptable.  Nurses would be required to complete training, certification and re-certification on a 
regular schedule.  Existing clinical educators would incorporate troponin POCT into existing curricula for 
ED nurses. These measures would be part of the accreditation process (described below) and would be 
expected to enhance the effectiveness of troponin POCT.  
Potential Laboratory Technician Issues:  Several consultants reported that there could be some 
“pushback” from lab technicians and their union about nurses being responsible for cardiac troponin 
POCT in the emergency department. This could affect the acceptability of emergency department 
troponin POCT at the inter-professional level and could also have a negative impact on its 
implementation and subsequent cost effectiveness if it is underused.  
Laboratory Technician Turnover Rates:  One final health human resource (HHR) contextual factor 
we identified relates to lab technician turnover rates in the province at this time.  Our consultants told 
us that there is a wave of lab technician staff changes underway; government research corroborates this 
view (66).  This is related, in part, to the province’s decision to have all provincial labs become 
accredited.  Our consultants suggested that seasoned lab technicians are taking early retirement or 
switching to new careers instead of going back to school and retraining in order to retain their jobs. 
Recruitment of lab staff in rural hospitals in this province has traditionally been challenging. 
Furthermore, the older generation of lab technicians was more likely to live in or near the community 
with the health centre where they worked and, once hired, would stay in the position for long periods of 
time.  More recently-hired lab technicians are more likely to commute from larger population centres 
and to stay in their positions for shorter periods of time.  Volatility in health human resources is 
perceived to be a risk for poorer performance in medical labs in terms of accuracy, efficiency and cost 
effectiveness (67,68).  An unstable lab technician workforce is expected to contribute to less clinical and 
cost-effective lab testing in general, and since lab technician staff are responsible for POCT quality 
assurance measures, an unstable workforce could affect POCT clinical and cost effectiveness as well.   
Organization of Health Services Factors 
The organization of health services supporting any point-of-care testing program is one area where 
research-based evidence is available.  
Site-specific organizational factors:  As mentioned previously, site-specific variables had significant 
impacts on turnaround time and time to discharge (42). Ryan and colleagues found that the individual 
NLCAHR October 2014 Troponin Point-of-Care Testing in Emergency Departments in Newfoundland 
and Labrador 
45 
test sites, with their own unique combination of organizational features, had a significant effect in 
mediating the clinical effectiveness, efficiency and cost effectiveness of emergency department troponin 
POCT.18  Although the authors could not definitively identify which features were responsible, they 
concluded that the overall effectiveness of emergency department POCT in general is critically 
influenced by the successful implementation of ancillary services and system protocols.  
Accreditation:  A major contextual factor regarding the organization of health services in 
Newfoundland and Labrador is the recently-adopted accreditation requirements for lab testing.  
Accreditation for point-of-care testing will go into effect in 2015 and requirements will include designing 
a certification program for lab staff, designating a resource person in each lab responsible for overseeing 
lab testing and quality assurance, implementing a data collection and analysis system, and establishing a 
range of other quality assurance measures including quality control protocols. Lab staff will be 
responsible for POCT quality control measures, while the clinical staff (i.e., nurses) will administer the 
point-of-care tests.  Our consultations indicate that having these standards, policies and practices in 
place is expected to enhance the clinical and cost effectiveness of troponin POCT compared to 
conditions without a standardized accreditation system (as was the case in the province until recently).  
Newer protocols vs. older standards:  There has been confusion among healthcare workers about 
new accreditation requirements.  In particular, workers have questioned why previously administered 
POCT, like blood glucose glucometers, were stopped and why their re-implementation will include more 
stringent quality control and quality assurance measures. Our consultations indicated that some clinical 
staff view the new version of the tests as added work (instead of seeing it as the same work with 
different standards of practice). Some lab technicians are concerned that the clinical staff will not be 
sufficiently rigorous with the testing equipment, and as a result, they do not want to be responsible for, 
or accountable for, POCT devices. Our consultants believe that these issues will need to be addressed 
and clarified in order for cardiac troponin POCT to be implemented effectively and efficiently. 
Need for Effective Monitoring: A second issue related to accreditation is effective monitoring of POCT 
performance to detect anomalies and errors. This requires the collection, tracking, compilation and 
analysis of data from individual POCT devices. Local lab technicians will be responsible for much, if not 
all, of the data collection at the hospital level, while the compilation of hospital level data will occur at 
the sub-regional and regional levels. Our consultations indicate that there have been some major 
challenges in integrating data from multiple hospitals and/or sub-regions, and these challenges could 
pose problems for effective monitoring of POCT devices across RHAs. Our consultants also told us that 
the collection, review and analysis of such potentially large pools of data will require additional human 
resources. These factors could potentially reduce the clinical and cost effectiveness of troponin POCT 
testing at the regional or provincial level, as well as other types of point-of-care testing (e.g., blood 
clotting POCT or liver function POCT) that may be considered in the future. 
                                                          
18
 The authors did not test individual organization features as independent variables, but rather identified the 
mediating effects of the organizational features through post hoc tests. 
NLCAHR October 2014 Troponin Point-of-Care Testing in Emergency Departments in Newfoundland 
and Labrador 
46 
Economic Factors 
Economic contextual factors that will have an impact on the cost effectiveness of troponin POCT testing 
in Newfoundland and Labrador must be considered when implementing the tests in smaller hospitals 
and health clinic emergency departments. 
Offsetting the cost of patient transfers: One major economic contextual factor when considering the 
use of cardiac troponin point-of-care tests is the cost of transferring a patient from one institution to 
another via ambulance to be tested. An emergency department cardiac troponin POCT program would 
reduce the need for such transfers by screening out patients who are negative for ACS, while confirming 
the need for transfers in those patients requiring care in a larger healthcare centre.  
Reduced demand for callback:  An emergency department cardiac troponin POCT may also reduce 
the need for lab staff callback, which requires a minimum pay period of three hours.  
As a result of an anticipated reduced demand for patient transfers and lab technician callbacks, the cost 
effectiveness of emergency department cardiac troponin POCT may be higher in NL compared to that 
reported in the research literature. 
Factors with the potential to increase costs:  Two economic contextual factors could decrease the 
local cost effectiveness of emergency department cardiac troponin POCT. The first involves the 
increased time for developing, implementing and maintaining the quality control and other quality 
assurance measures required for accreditation that were not previously standardized across hospitals in 
Newfoundland and Labrador. The second is the cost of designing, implementing and maintaining a 
comprehensive data collection and monitoring system to evaluate POCT in general and emergency 
department troponin POCT specifically.  The available evidence does not appear to include these costs 
for practices and infrastructure that may already exist in other jurisdictions.  Accordingly, the actual cost 
effectiveness of ED cardiac POCT for troponin, and other POCT tests, may be lower in Newfoundland and 
Labrador than what is reported in the literature we have reviewed. 
Political Factors 
Two main types of political factors were identified by our consultants as being unique to the 
Newfoundland and Labrador context.  
Public perception of biomedical testing in the province: The healthcare system of Newfoundland 
and Labrador has had, over the past ten years, numerous episodes where lab testing results have been 
found to be in error. As a result, the public has a certain lack of trust in the capacity of the provincial 
health care system to provide adequate testing, quality control and/or monitoring. While our 
consultants agreed that patients and their caregivers are still likely to accept a new technology like 
emergency department troponin POCT, any problems with the new technology, especially in its early 
stages, could significantly lower its acceptability by the public and possibly its use by clinical staff. 
Possible conflict within the healthcare system: The second political factor identified by our 
consultants relates to the potential for conflict from within the healthcare system. Conflicts may arise 
from either the laboratory technicians and/or the emergency department clinical staff. Laboratory 
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technicians have voiced resistance to being held responsible for quality assurance when clinical staff are 
administering POCT tests. They have also protested the recently-announced regional centralization of 
central lab testing. In terms of the clinical staff, our consultants told us that there are some complaints 
about the recent restrictions on POCTs, and in the case of some tests like glucometers, reintroduction 
with additional quality control measures. Clinical staff may perceive the new accreditation-related 
measures as additional and unwanted work.  
In order for any POCT to be implemented successfully in the province, both laboratory and clinical 
healthcare workers will need to accept and support the new tests and the required quality assurance 
measures required by accreditation.  
Considerations for Decision Makers 
 
We list below considerations that health system decision makers may wish to take into account when 
considering emergency department cardiac troponin point-of-care testing for smaller hospital and 
health centres.  These suggestions are based on the synthesis findings as refracted through the 
professional perspectives of the clinicians, administrators, and decision makers on the project team, 
most of whom currently work within the provincial health system.  
1. Cardiac troponin point-of-care testing technology is sufficiently accurate and reliable to be used 
as a screening test for acute coronary syndrome in emergency departments in Newfoundland 
and Labrador. 
2. Hospital and regional level supports for POCT in the emergency department will strongly 
influence the effectiveness, efficiency and cost-effectiveness of cardiac troponin POCT. In 
particular, adherence to quality control measures and clinical protocols is required for POCT to 
realize its potential benefits. Emergency department physicians and nurses, and central lab 
technicians, will need to accept any proposed POCT to sustain quality control measures and 
protocols. 
3. The requirement for accreditation for POCT in the province will help ensure that the appropriate 
quality control measures and protocols are implemented and sustained. However, health 
human resource challenges are potentially significant, particularly for smaller hospitals in 
Newfoundland and Labrador; these challenges could have an impact on sustaining those 
measures and protocols. 
4. Tracking and monitoring are crucial requirements of POCT quality control. In order to properly 
implement POCT, the RHAs will need to be able to compile and analyze data from multiple sites 
in a timely and effective manner. 
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5. When implemented properly and used appropriately, cardiac troponin POCT, used as a 
screening test, does not increase the risk of adverse events or readmission rates compared to 
central lab testing; furthermore this POCT significantly reduces the Turnaround Time for test 
results, and has the potential to reduce other emergency department time outcomes and to 
improve patient throughput.   
6. When implemented properly, cardiac troponin POCT, used as a screening test, can reduce time 
to anti-ischemic therapy for high-risk patients and time to a negative diagnosis among low-risk 
patients, especially in hospitals and health centres without an operating central lab. 
7. The evidence does not provide a clear indication of the economic impacts of ED cardiac troponin 
POCT in Newfoundland and Labrador, though it does suggest that POCT will be the most cost-
effective in hospitals without 24/7 central lab services. 
In addition to the foregoing considerations, which are based on the available research-based evidence 
and the Newfoundland and Labrador context, decision makers may wish to consider the continuing 
advances in technology for point-of-care testing. Advances in miniaturization, bioassays, biosensors and 
health informatics are happening at a rapid pace, while the costs of these technologies continue to 
decrease.  As a result of this technological context, the number and variety of point-of-care testing 
devices can be expected to proliferate and to extend into emergency departments and other healthcare 
settings including acute care, primary care, long-term care and, increasingly, into the patient’s home.  
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